Preferred Pharmaceuticals Recalls Metformin HCl ER 500 mg Due to NDMA Contamination and CGMP Deviations
Preferred Pharmaceuticals, Inc. initiated a Class II recall of Metformin HCl Extended Release Tablets USP 500 mg due to N-Nitrosodimethylamine (NDMA) levels exceeding acceptable limits, stemming from CGMP deviations. This event, now terminated, underscores persistent nitrosamine risks in generic drug supply chains. Procurement and regulatory teams must enhance supplier scrutiny and impurity testing protocols.
FDA Findings: CGMP Deviations and NDMA Contamination in Metformin HCl ER
Preferred Pharmaceuticals, Inc., based in Anaheim, California, initiated a Class II recall (D-0077-2021) on November 1, 2020, for its Metformin HCl Extended Release Tablets USP 500 mg. The critical finding by the FDA was the detection of N-Nitrosodimethylamine (NDMA) levels that exceeded the Acceptable Daily Intake Limit, directly attributed to Current Good Manufacturing Practice (CGMP) deviations. This specific recall involved 99 bottles, totaling 9,990 extended-release tablets, manufactured by Time-Cap Labs, Inc. in Farmingdale, New York. The product, a generic equivalent for Glucophage XR, carried NDC #: 68788-6932-1 and was distributed to two physician's offices in Florida. The recall was officially terminated on May 20, 2024, indicating the FDA deemed the firm's corrective actions sufficient for this particular event. For procurement directors, this incident highlights the imperative of stringent supplier qualification and continuous monitoring, even for established generic products. Regulatory affairs heads must recognize that CGMP compliance failures can lead directly to critical impurity issues, necessitating robust quality agreements and audit programs that extend to contract manufacturers like Time-Cap Labs, Inc.
Company and Product Profile: Preferred Pharmaceuticals' Role in the Generic Metformin Market
Preferred Pharmaceuticals, Inc., operating from 1250 N Lakeview Ave Ste O, Anaheim, CA 92807-1801, acted as the recalling firm for the Metformin HCl Extended Release Tablets USP 500 mg. While Preferred Pharmaceuticals initiated the recall, the product itself was manufactured by Time-Cap Labs, Inc. in Farmingdale, NY. This distinction is crucial for supply chain VPs and business development executives. Preferred Pharmaceuticals distributed a relatively small quantity of the affected product, 99 bottles, to a limited geographical area, specifically two physician's offices in Florida. The product is a widely used generic for Glucophage XR, a critical medication for diabetes management. The NDC number associated with the recalled product is 68788-6932-1, with specific lot codes E0620F (Exp. 12/31/2021) and G2020M (Exp. 04/30/2022). This event underscores that even smaller distributors, when recalling products manufactured by third parties, must possess robust quality oversight mechanisms to prevent and detect CGMP failures that can introduce harmful impurities like NDMA. Procurement teams must scrutinize the entire supply chain, from API sourcing through manufacturing and distribution, to identify all entities involved and their respective quality responsibilities.
Supply Chain Exposure: Limited Distribution, Broader Implications for Metformin Sourcing
The distribution pattern for the recalled Metformin HCl Extended Release Tablets USP 500 mg was notably limited, reaching only two physician's offices in Florida. With a quantity of 99 bottles, representing 9,990 tablets, the immediate public health risk and direct supply chain disruption from this specific recall were contained. However, the underlying cause—NDMA contamination due to CGMP deviations—carries significant implications for the broader generic Metformin supply chain. This incident serves as a critical reminder for supply chain VPs that even minor distribution channels can expose the entire network to regulatory scrutiny and product integrity risks if upstream manufacturing quality is compromised. The fact that the manufacturer was Time-Cap Labs, Inc., a separate entity from the recalling firm, highlights the complexities of multi-party supply chains in pharmaceuticals. Business development executives considering partnerships or acquisitions in the generic diabetes medication sector must conduct thorough due diligence on all manufacturing partners' quality systems and historical compliance records. Procurement directors should not be complacent about small-scale recalls, as they often signal systemic vulnerabilities that could manifest more broadly across other product lines or larger distribution networks.
Mitigating Risk: Strategic Sourcing and Enhanced Testing for Metformin Suppliers
Given the persistent challenges with nitrosamine contamination, as evidenced by this Preferred Pharmaceuticals recall and other industry events like Teva's Metformin Recall, procurement directors must proactively reassess their sourcing strategies for Metformin and other at-risk molecules. Diversification of the supplier base is paramount, extending beyond primary manufacturers to include alternative API and finished product suppliers across different geographies. This strategy reduces reliance on any single entity and provides resilience against quality failures or regulatory actions. Regulatory affairs heads should mandate enhanced impurity testing protocols, specifically focusing on nitrosamines like NDMA, at multiple points in the supply chain—from incoming raw materials and excipients to finished product release. Qualification timelines for new suppliers must incorporate rigorous audits of their CGMP compliance, impurity control strategies, and change management processes. Supply chain VPs should explore partnerships with suppliers demonstrating advanced analytical capabilities and a proactive approach to nitrosamine risk assessment, rather than simply meeting minimum regulatory requirements. This includes evaluating their synthesis routes, solvent choices, and storage conditions to minimize the potential for nitrosamine formation.
Broader Regulatory Context: Persistent Nitrosamine Contamination and CGMP Risks
The recall of Metformin HCl Extended Release Tablets by Preferred Pharmaceuticals due to NDMA contamination is not an isolated incident but rather indicative of a systemic challenge within the pharmaceutical industry, particularly concerning nitrosamine impurities. The ChemLifeIntel Knowledge Graph highlights similar events, such as Teva's Metformin Recall, which also stemmed from NDMA contamination and CGMP risks. This pattern underscores that the issue extends beyond individual firms and points to broader vulnerabilities in manufacturing processes and quality control across the generic drug sector. For regulatory affairs heads, this necessitates a proactive and comprehensive approach to nitrosamine risk management across all product portfolios, not just Metformin. This includes reviewing all drug products for potential nitrosamine formation pathways, implementing robust risk assessments, and updating analytical methods to detect these impurities at trace levels. Business development executives must factor this heightened regulatory scrutiny into their market entry strategies and partnership evaluations, prioritizing companies with a proven track record of stringent quality control and proactive impurity management. The FDA's consistent enforcement actions, even for smaller-scale recalls, signal a zero-tolerance policy for impurities exceeding acceptable daily intake limits, reinforcing the need for continuous vigilance.
Post-Recall Actions and Future Compliance Expectations for Pharmaceutical Firms
The termination of the D-0077-2021 recall on May 20, 2024, signifies that the FDA has acknowledged Preferred Pharmaceuticals' corrective actions for the specific affected batches of Metformin HCl Extended Release Tablets. While this closure provides a degree of resolution for the immediate event, it does not diminish the ongoing regulatory expectations for CGMP compliance and impurity control. For regulatory affairs heads, this means that continuous monitoring and proactive risk management remain critical. Firms must demonstrate not only that they have addressed the root causes of the NDMA contamination but also that they have implemented robust systems to prevent recurrence across all products and manufacturing sites, including those of their contract manufacturers like Time-Cap Labs, Inc. Procurement directors should integrate recall termination status into their supplier performance metrics, but also demand evidence of sustainable corrective and preventive actions. Supply chain VPs must recognize that regulatory scrutiny on nitrosamine impurities will persist, requiring ongoing investment in quality infrastructure, analytical capabilities, and personnel training. The industry must move beyond reactive recalls to proactive quality assurance, ensuring that all products consistently meet safety and quality standards from development through distribution to safeguard patient health and maintain market access.